Key Takeaways EXEL rose on positive STELLAR-303 results, showing OS benefit for zanzalintinib plus Tecentriq in CRC. Cabometyx sales should gain from label expansions and strong demand in RCC. EXEL raised 2024 revenue guidance by $100M, backed by Cabometyx momentum and pipeline progress.Exelixis (EXEL) has put up a stellar performance so far this year. Shares of the biotech company have rallied 35.2% in the past three months compared with the industry’s growth of 11.8%. The stock has also outperformed the ...

One formula to generate strong returns on equity markets involves investing small amounts of money in top stocks regularly over long periods. Buying fractional shares is one way to apply this strategy, but it's also possible to find attractive corporations at already-affordable prices.Here are two excellent examples in the healthcare industry: Pfizer (PFE 0.30%) and Exelixis (EXEL 3.72%). These drugmakers are worth investing in, and both are changing hands for under $50 apiece. Here is what investors need t ...

Exelixis (EXEL) shares soared 7.4% in the last trading session to close at $43.37. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 4.8% loss over the past four weeks.Shares rallied following the company's announcement that the late-stage STELLAR-303 study met one of its two dual primary endpoints, demonstrating a statistically significant improvement in overall survival (OS) for the intent-to-treat (ITT) population when treated w ...

Key Takeaways More on EXEL's STELLAR-303 Study on Zanzalintinib Zanzalintinib is a third-generation oral tyrosine kinase inhibitor that inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER. The STELLAR-303 study met one of its two dual primary endpoints, demonstrating a statistically significant improvement in overall survival (OS) for the intent-to-treat (ITT) population when treated with zanzalintinib in combination with Tece ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Exelixis (EXEL) has performed well this year. Shares of the biotech company have gained 28.1% year to date against the industry’s decline of 3.5%. The stock has outperformed the sector and the S&P 500 Index in this timeframe.EXEL Outperforms Industry, Sector & S&P 500Image Source: Zacks Investment ResearchThe company's upbeat performance can be attributed to its strong quarterly results, raised guidance, label expansion of Cabometyx (cabozantinib) and efforts to increase shareholders' returns.In March, the ...

Core Viewpoint - Exelixis, Inc. reported strong first-quarter 2025 results, exceeding earnings expectations and showing significant revenue growth driven by its lead drug, Cabometyx [1][2]. Financial Performance - Adjusted earnings were 62 cents per share, surpassing the Zacks Consensus Estimate of 42 cents, and up from 17 cents per share in the same quarter last year [1][2]. - Net revenues reached $555.4 million, exceeding the Zacks Consensus Estimate of $503 million, and reflecting a 31% year-over-year increase [2]. - Net product revenues were $513.3 million, a 36% increase year-over-year, primarily due to higher sales volume and average net selling price of Cabometyx [3]. Product Performance - Cabometyx generated revenues of $510.9 million, beating the Zacks Consensus Estimate of $433.7 million and the model estimate of $457.3 million [4]. - Collaboration revenues totaled $42.2 million, a decrease of 10% from $46.7 million in the previous year, attributed to lower royalty revenues from collaboration partners [5]. Expense Management - Research and development expenses amounted to $212.2 million, down 7% year-over-year, due to reduced collaboration costs and lower clinical study costs [6]. - Selling, general and administrative expenses increased by 20% year-over-year to $137.2 million, driven by higher personnel and marketing expenses [6]. Guidance and Future Outlook - Exelixis raised its 2025 sales guidance, now expecting total revenues between $2.25 billion and $2.35 billion, up from the previous range of $2.15 billion to $2.25 billion [8]. - The company anticipates research and development expenses in the range of $925 million to $975 million and selling, general and administrative expenses between $475 million and $525 million for 2025 [10]. Regulatory and Pipeline Updates - In March 2025, Exelixis received FDA approval for the label expansion of Cabometyx for treating neuroendocrine tumors, making it the first systemic treatment approved for this indication [11][12]. - The company is also developing zanzalintinib, with promising results from a phase Ib/II trial showing better efficacy when combined with Tecentriq [13][14].

TUESDAY, MAY 13, 2025 First Quarter 2025 Financial Results Commercial Update Development Update Pipeline & Discovery Update Nasdaq: EXEL Today's Agenda Introduction First Quarter 2025 Highlights Financial Results & Guidance Q&A Susan Hubbard EVP, Public Affairs and Investor Relations Michael M. Morrissey, Ph.D. President and CEO Chris Senner EVP and CFO PJ Haley EVP, Commercial Amy Peterson, M.D. EVP, Product Development and Medical Affairs and CMO Dana T. Aftab, Ph.D. EVP, Discovery and Translational Resea ...